December 2015 | Volume 4, Issue 6

Moving Away from Fusion by Treating the Pain Generator: The Secrets of an Endoscopic Master
Anthony T. Yeung
Editorial: J Spine 2015, 4: e121
DOI: 10.4172/2165-7939.1000e121

Tubercle Bacilli in Spinal Tuberculosis - Morphology, Cell Wall Features, Behaviour and Drugs
Myung-Sang Moon, Hanlim Moon and Sung-Soo Kim
Review Article: J Spine 2015, 4: 265
DOI: 10.4172/2165-7939.1000265

Injectable Bone Substitute Paste Based on Hydroxyapatite, Gelatin and Streptomycin for Spinal Tuberculosis
Hindita Nar Maulda, Dyah Hikmatiati and Anek Setya Budisatia
Research Article: J Spine 2015, 4: 250
DOI: 10.4172/2165-7939.1000250

Cauda Equina Lymphoma - Case Report and Review of Literature
Pedro R. Basci, Luan Lucena, Rafael Augusto Españoeh, Tânia Abrantes de Lacerda Almeida, Matheus Pinto Brunet, Wellington César de Souza, Eduardo Felipe Martellini Baldassara, Laura Regina Toffoli Roso, Luiza Veronica Giacomini, Fernando Luiz Giacomini, Adaildo Baseggi Malta inn and Charles André Carazzo
Case Report: J Spine 2015, 4: 287
DOI: 10.4172/2165-7939.1000287

Non-Traumatic Anterior Atlas Fracture Following C1 Laminectomy - Case Report
Keshi Tsunoda, Wataru Haraqtji, Naoki Kitagawa and Takayuki Matsuo
Research Article: J Spine 2015, 4: 268
DOI: 10.4172/2165-7939.1000268
Degenerative Cervical Spondylosis: Is Instability the Primary Point of Pathogenesis?

Atul Goel MOH

Commentary: J Spine 2015, 4: 271

DOI: 10.4172/2165-7939.1000271

Ankylosing Spondylitis in Association with Non-Hodgkin’s Lymphoma: Successful Anti-TNF Alpha Treatment

Augusta Ortolan, Anna La Salvia, Managrazia Lorenczo, Paola Fraitonardo, Dario Marro, Leonardo Punzi and Roberta Ramondi

Case Report: J Spine 2015, 4: 272

DOI: 10.4172/2165-7939.1000272

Transforaminal Lumbar Interbody Fusion (TLIF) Using Pedicle Screws with Mobility

Hōkōki Ohita, Yoshikuki Matsumoto, Yoshikazu Nakayama, Tsubasa Sakai, Youhei Iwuchi, Masato Tatsuno, Hiroaki Kida and Yoshisharu Takeyasu

Research Article: J Spine 2015, 4: 273

DOI: 10.4172/2165-7939.1000273

Current Status of Interspinous Posterior Devices in USA and Italy: Finally the Pandoras Vase has been Uncovered

Alessandro Landi, Fabrizio Gregori, Biagio la Pira, Angela Ambrosone and Roberto Delfini

Commentary: J Spine 2015, 4: 274

DOI: 10.4172/2165-7939.1000274

Efficacy of Nucleo-Annuloplasty Using Disc-Fx in Lumbar Disc Herniation

Chan Hong Park and Sang Ho Lee

Research Article: J Spine 2015, 4: 275

DOI: 10.4172/2165-7939.1000275
Biochemical Structure and Functions of the Lumbar Disc after an Autologous Chondrocyte Transplantation (ACT) Evaluated by Studies of Two Operated Cases of Repeated Disc Herniation

Abaslam F, Marzalek P, Glowacki M, Witka A, Sierczukowski T and Czermicki Z

Research Article: J Spine 2015, 4: 276

DOI: 10.4172/2155-7939.1000276

Special Features of - OMICS International Journals

700+ Open Access journals
21 Days rapid review process
50000 Editorial team
15 Million readers

Publication immediately after acceptance
Quality and quick editorial, review processing

OMICS International Journals

Special Features of - OMICS International Conferences

OMICS International Organises 3000+ Conferences Every Year across USA, Europe & Asia

Well organized scientific program
21 Days rapid review process
50000 Editorial team
Renowned speakers and scientists across the globe
Poster presentations and world class exhibits
Panel discussions & interactive sessions
Perfect platform for global networking

OMICS International Conferences

Peer Reviewed Journals

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals

Journals by Subject

- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Biomedical Sciences
- Business & Management
- Chemical Engineering
- Chemistry
- Clinical Sciences
- Computer Science
- Economics & Accounting
- Engineering
- Environmental Sciences
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Geology & Earth Science
- Immunology & Microbiology
- Informatics
- Materials Science
- Mathematics
- Medical Sciences
- Nanotechnology
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
- Physics
- Plant Sciences
- Social & Political Sciences
- Veterinary Sciences

OMICS International

Clinical & Medical Journals

- Anesthesiology
- Cardiology
- Clinical Research
- Dentistry
- Dermatology
- Diabetes & Endocrinology
- Gastroenterology
- Genetics
- Haematology
- Healthcare
- Immunology
- Infectious Diseases
- Medicine
- Microbiology
- Molecular Biology
- Nephrology
- Neurology
- Nursing
- Nutrition
- Oncology
- Ophthalmology
- Orthopaedics
- Pathology
- Pediatrics
- Physical Therapy & Rehabilitation
- Psychiatry
- Pulmonology
- Radiology
- Reproductive Medicine
- Surgery
- Toxicology

International Conferences 2017-18

Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Conferences by Country

- USA
- Spain
- Poland
- Australia
- Canada
- Austria
- UAE
- China
- Turkey

Medical & Clinical Conferences

- Microbiology
- Diabetes & Endocrinology
- Nursing
- Oncology & Cancer
- Cardiology
- Dentistry

Conferences By Subject

- Pharmaceutical Sciences
- Pharma Marketing & Industry
- Agri. Food & Aqua
<table>
<thead>
<tr>
<th>Contact Us</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Agric. &amp; Aquaculture Journals</strong></td>
</tr>
<tr>
<td>Dr. Kranthi</td>
</tr>
<tr>
<td><a href="mailto:agricb@omicsonline.com">agricb@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-715-7001 Ext: 9040</td>
</tr>
<tr>
<td><strong>Biochemistry Journals</strong></td>
</tr>
<tr>
<td>Ganga A</td>
</tr>
<tr>
<td><a href="mailto:biochemjournals@omicsonline.com">biochemjournals@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9037</td>
</tr>
<tr>
<td><strong>Business &amp; Management Journals</strong></td>
</tr>
<tr>
<td>Ronald</td>
</tr>
<tr>
<td><a href="mailto:business@omicsonline.com">business@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9042</td>
</tr>
<tr>
<td><strong>Chemistry Journals</strong></td>
</tr>
<tr>
<td>Gabriel Shaw</td>
</tr>
<tr>
<td><a href="mailto:chemistryjournals@omicsonline.com">chemistryjournals@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9040</td>
</tr>
<tr>
<td><strong>Clinical Journals</strong></td>
</tr>
<tr>
<td>Datta A</td>
</tr>
<tr>
<td><a href="mailto:clinicaljournals@omicsonline.com">clinicaljournals@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9037</td>
</tr>
<tr>
<td><strong>Engineering Journals</strong></td>
</tr>
<tr>
<td>James Franklin</td>
</tr>
<tr>
<td><a href="mailto:engineeringjournals@omicsonline.com">engineeringjournals@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9042</td>
</tr>
<tr>
<td><strong>Food &amp; Nutrition Journals</strong></td>
</tr>
<tr>
<td>Katie Wilson</td>
</tr>
<tr>
<td><a href="mailto:nutritionjournals@omicsonline.com">nutritionjournals@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9042</td>
</tr>
<tr>
<td><strong>General Science</strong></td>
</tr>
<tr>
<td>Andrea Jansen</td>
</tr>
<tr>
<td><a href="mailto:generalscience@omicsonline.com">generalscience@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9043</td>
</tr>
<tr>
<td><strong>Genetics &amp; Molecular Biology Journals</strong></td>
</tr>
<tr>
<td>Anna Melissa</td>
</tr>
<tr>
<td><a href="mailto:geneticsonline@omicsonline.com">geneticsonline@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9006</td>
</tr>
<tr>
<td><strong>Immunology &amp; Microbiology Journals</strong></td>
</tr>
<tr>
<td>Gada Gorant</td>
</tr>
<tr>
<td><a href="mailto:immunomicrobiology@omicsonline.com">immunomicrobiology@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9044</td>
</tr>
<tr>
<td><strong>Materials Science Journals</strong></td>
</tr>
<tr>
<td>Rachel Green</td>
</tr>
<tr>
<td><a href="mailto:materialscio@omicsonline.com">materialscio@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9039</td>
</tr>
<tr>
<td><strong>Medical Journals</strong></td>
</tr>
<tr>
<td>Nirmala Arora</td>
</tr>
<tr>
<td><a href="mailto:medicaljournals@omicsonline.com">medicaljournals@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9038</td>
</tr>
<tr>
<td><strong>Neuroscience &amp; Psychology Journals</strong></td>
</tr>
<tr>
<td>Nathan T</td>
</tr>
<tr>
<td><a href="mailto:neuropsychology@omicsonline.com">neuropsychology@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9041</td>
</tr>
<tr>
<td><strong>Pharmaceutical Sciences Journals</strong></td>
</tr>
<tr>
<td>Ann Jose</td>
</tr>
<tr>
<td><a href="mailto:pharmajournals@omicsonline.com">pharmajournals@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9007</td>
</tr>
<tr>
<td><strong>Social &amp; Political Science Journals</strong></td>
</tr>
<tr>
<td>Steve Harvey</td>
</tr>
<tr>
<td><a href="mailto:socialpolitics@omicsonline.com">socialpolitics@omicsonline.com</a></td>
</tr>
<tr>
<td>1-702-714-7001 Ext: 9042</td>
</tr>
</tbody>
</table>

© 2006-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Injectable Bone Substitute Paste Based on Hydroxyapatite, Gelatin and Streptomycin for Spinal Tuberculosis

Hendra Nur Maulida, Dyah Hikmawati and Aniek Setyia Budiatin

ABSTRACT

World Health Organization (WHO) in 2005 reported that cases of tuberculosis (TB) in the world occur more than 8 million annually and 5-10% was attacked in spine. The most effective treatment of spinal TB is evacuation of infected bone segments and fills with bone graft. It has been synthesized and characterized of Injectable Bone Substitute (IBS) paste based on hydroxyapatite, gelatin and streptomycin. IBS paste synthesized by mixing hydroxyapatite and gelatin 20% w/w with 75:25, 70:30, 65:35 and 60:40 ratio and streptomycin 10 wt%. The mixture was then added with hydropropyl methylcellulose (HPMC) 4% w/v as suspending agent. In vitro characterization performed includes acidity (pH), injectability test, setting time, cytotoxicity (MTT assay) and microbacterium test. Acidity test results indicate a fourth variation of the samples had pH values approaching normal body pH (7.3 to 7.6) and is able to maintain stability when measured in 7 days. Injectability test results indicate IBS paste is injectable with the highest percentage of the injectability value at 97.74% ± 0.19%. IBS paste has been setting within 30 minutes to 1 hour when injected on hydroxyapatite scaffold that resembles the bone cavity and is able to cover the pore scaffold seen from the Scanning Electron Microscope (SEM). Scaffold pore size is smaller from range of 780.8 to 835.4 μm into 225.2 μm. MTT assay results showed that IBS paste is not toxic and experiencing proliferation (viability >100%) that are expected to trigger osteoblast cell growth when applied. Microbacterium test results showed that IBS paste is an antibacterial seen from inhibition zone diameter of Staphylococcus aureus and has a high strength-sensitive antibacterial. Thus, hydroxyapatite, gelatin and streptomycin composites had qualified as injectable bone substitute which applied in cases of spinal tuberculosis.

KEYWORDS: Spinal tuberculosis; Injectable bone substitute; Hydroxyapatite; Gelatin; Streptomycin; Hydropropyl methylcellulose

INTRODUCTION

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis which are systemic and can manifest in almost all organs of the body with the lungs as the primary infection site [1]. World Health Organization (WHO) in 2005 reported that TB cases in the world occur more than 8 million per year and 34% of them occur in Southeast Asia, including Indonesia [2]. Indonesia is the 3rd largest contributor to cases of TB after India and China with every 4 minutes there was one patient who died and transmission occurs every 2 seconds [1]. The incidence of extra-pulmonary TB occurs in 25-30% and 5-10% of which occur in the bones and joints and the most attacking in the spine. Bone TB cases is diagnosed when the symptoms have started after one year [4].

Spinal infection by TB could potentially cause serious morbidity including neurological deficits and permanent spinal deformity. Handling of spinal TB in general is giving antituberculosis drugs, immobilization using gips also orthopedic and neurological surgical intervention [5]. Surgical intervention will be taken when after 3-4 weeks of antituberculosis drug administration and conservative therapy does not give a good response. In this case, the most effective spinal lesions treated with immediate surgery to evacuate TB bacteria, take the infected bone and fill the spinal segment involved with bone graft to promote healing and achieve spinal stability [6].

Commercially, the material that can be used as bone graft is Hydroxyapatite (HA). Hydroxyapatite is a bioceramics material that is biocompatible and bioactive because of its mineral content, both physically and chemically very similar to bone [7]. Hydroxyapatite can be obtained from the bones of mammals, fish bones, shells and other materials based on calcium phosphate. However, hydroxyapatite is brittle so that hard formed according to the required implant materials [8]. Some researchers then developed a composite material of hydroxyapatite with polymers to improve the mechanical properties, one of which gelatin. Gelatin as a polymer derived from natural materials is biodegradable, biocompatible and non-toxic. Gelatin is widely used as space filler because it is easy to set up [9].

Some use in orthopedics requires injectable biomaterial graft which serves as a filler. Injectable system is ready to use, can follow the shape of bone cavity to be filled and polymerized in situ after being injected. To produce composite injectable, it is required a gel as matrix material maker. Polymers are widely used came from the class of cellulose such as Hydroxypropyl Methylcellulose (HPMC) [8]. HPMC is a water-soluble polymer and is widely used in the food industry as a thickening due to high viscosity [10]. Manufacture of injectable bone substitute (IBS) has been done by several researchers including Weiss et al. [11] with IBS based on calcium phosphate and Shen et al. [12] with IBS based on alendronate and calcium phosphate.

In this study, we have been synthesized and characterized of IBS paste based on nano-hydroxyapatite, gelatin and streptomycin for spinal TB cases. The use of nano-sized hydroxyapatite is expected to easily fit into the pores of the bones thoroughly. While the streptomycin is antibiotic, the primary antituberculosis drugs produced by the soil fungus Streptomyces griseus. This drug is readily soluble in water [13].

*Corresponding author: Hendra Nur Maulida, Biomedical Engineering Study Program, Faculty of Science and Technology, The University of Airlangga, Surabaya, Indonesia. Tel: +62 856-5524-2442; E-mail: hendramaulida@gmail.com

Received September 09, 2015; Accepted October 31, 2015; Published November 02, 2015


Copyright: © 2015 Maulida HN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The main target of streptomycin is working mechanism at the level of ribosome [14].

Characterization in this study include acidity test to determine degree of acidity of IBS to reach the body's normal pH and its stability as paste, injectability test to measure the ability of IBS can come out of injections, setting time to determine the time of IBS experience setting when injected, MTT assay test to determine the cytoxicity of IBS when tested in fibroblast BHK-21 cells and microbiacterium test to determine the IBS resistance against bacterial pathogens using S. aureus. These characterizations are to evaluate the ability of hydroxyapatite, gelatin, and streptomycin as injectable bone substitute for spinal TB cases.

Materials and Methods

Materials

Tools used include digital scales Mettler Toledo, magnetic stirrer Yellow MAG HS 7, deep freezer, freeze dryer, thermometer, Terumo Syringe 12 ml and 5 ml, glassware (vial bottles, beaker glass and petri dish), micrometers couplers, stopwatch, viscoseteter VT-04R RION, pH meter Benchtop OAKTON, Scanning Electron Microscope (SEM) FEI Inspect S50 Japan, a set of MTT assay and microbiacterium test.

Materials used include nano-hydroxyapatite of Barramundi fish from the National Nuclear Energy Agency (BATAN) Jakarta, cow skin gelatin from 150 bloom Rousselot (Guangdong, China), streptomycin sulfate from PT. Meiji Indonesian Pharmaceutical Industries, Hydroxypropyl Methylcellulose (HPMC) from Sigma Aldrich, hydroxyapatite scaffold from Tissue Bank of Dr. Soetomo hospital Surabaya, Staphylococcus aureus, Trypticase Soy Broth (TSB) and microbiology nutrient agar from Merck.

Synthesis of injectable bone substitute paste

IBS paste made in 4 variations in the composition of hydroxyapatite-gelatin that is 75:25, 70:30, 65:35 and 60:40 (w/w). Gelatin 20% w/v is dissolved in distilled water at 40°C. Hydroxyapatite with variations in composition put into the gelatin solution then added streptomycin 10 w% as a local dose [13]. Meanwhile, HPMC 4% w/v is dissolved in distilled water at 90°C. Furthermore HPMC solution is added to a solution of gelatin, hydroxyapatite and streptomycin at 40°C and the mixture was stirred for six hours to produce a white IBS paste.

Acidity (pH) test

Acidity test is used to determine the degree of acidity and the stability of IBS as paste when measured in 7 days. Measurement performed with placing electrodes into the sample and pH will automatically appear on the screen of pH meter and make sure that the samples are measured at room temperature.

Injectability test

Injectability conducted to evaluate the ability of IBS paste can come out of the injection within a certain time. IBS first measured the viscosity to ensure the applicable value as injectable system. Measurement results showing viscosity IBS in units dPa.s. Furthermore, injectability test performed using the reference method reported by Shen et al. [12].

In this test, we used the syringe 12 ml with inner diameter of 1.5 cm and needle with inner diameter of 12 mm. Mass of IBS paste before and after injection within 2 minutes measured and its injectability calculated using the following equation:

\[ \text{Injectability} \% = \frac{\text{mass expelled from the syringe}}{\text{total mass of the paste before injecting}} \times 100 \% \]

Each test was repeated five times and the average value was calculated as a result of percentage of injectability.

Setting time

Setting time testing was performed using hydroxyapatite scaffold that has been freeze-dried as a substrate [16]. Hydroxyapatite scaffold mass were measured to observe the changes that occur after setting. Testing was performed by injecting IBS samples into the scaffold vertically. Time counting begins when IBS penetrated into the scaffold pores and stopped when the surface of the scaffold was completely dry and covered by the IBS. The test results also were observed using SEM to determine the surface morphology of microscopic scaffold in sizes below 200 nm.

Cytotoxicity test with MTT assay

Cytotoxicity assay was performed using reagents MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] which comprises the step of culturing fibroblast Baby Hamster Kidney (BHK-21) cells, placing samples and reading the results. Optical cell density can be determined using Elisa Reader and use equation (2) to calculate the percentage of living cells.

\[ \% \text{Living Cells} = \frac{\text{OD Treatment} + \text{OD Media Control}}{\text{OD Cells Control} + \text{OD Media Control}} \times 100 \% \]

where : OD Treatment = optical density value of the sample after treatment

OD Cells Control = optical density value of the control cells

OD Media Control = optical density value of media control

\% Living Cells = the percentage of the number of cells after treatment

Microbacterium test

Microbacterium test is used to determine the IBS resistance against bacterial pathogens by looking at the profile of bacterial inhibition zone diameter for several days. Culture of one of Staphylococcus aureus (SA) suspended in 9 ml Trypticase Soy Broth (TSB) then cultured in incubator 60°C for 24 hours. Absorbance values of SA bacteria are calculated using UV-Visible Spectrometer. Nutrient agar was prepared as a medium for bacteria. IBS paste put in wells agar medium with four repetitions and observed inhibition zone diameter after incubation for 24 hours. IBS strength levels against bacterial resistance were evaluated by comparing clear zone diameter according to Table 1.

<table>
<thead>
<tr>
<th>Clear Zone Diameter</th>
<th>Microorganism Resistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;20 mm</td>
<td>Very Sensitive</td>
</tr>
<tr>
<td>10-20 mm</td>
<td>Sensitive</td>
</tr>
<tr>
<td>5-10 mm</td>
<td>Less Sensitive</td>
</tr>
<tr>
<td>&lt;5 mm</td>
<td>Resistant</td>
</tr>
</tbody>
</table>

Table 1: Strength rate of bacteria.

Results and Discussion

Acidity (pH) test

Degree of acidity (pH) becomes one of the important factors to evaluate the performance of IBS material when applied. From the measurement results, we obtained an average pH of each sample with variation composition of HA-gelatin 75:25, 70:30, 65:35 and 60:40 (w/w) respectively is 7.62, 7.54, 7.41 and 7.35. Graph stabality of IBS pH value can be seen in Figure 1.
Injectability test

IBS paste viscosity values were measured using viscometer showing a number of 120 dPa s and applicable in terms of injectability test results as shown in Figure 2. From the test results, it can be concluded that the four samples of IBS has a very good ability in terms of the percentage results approaching 100%. Best percentage of injectability owned by the sample C with HA-gelatin ratio at 65:35 (w/w) is equal to 97.74% ± 0.19%.

Setting time

Setting time performed using HA scaffold freeze-dried as a simulation of human bone parts. Media or substrates that have the same as the main constituent component of the sample will be able to trigger these components for neat and improve the crystallinity. From the test results, the final setting time raised about 30 minutes to 1 hour as shown in Figure 3.

Measurement results of mass scaffold before and after setting also showed an increase. This change is due to the scaffold HA synthesized by the method of freeze-dried produce a pore that allows the IBS to infiltrate so that the crystallinity increases and pore seemed closed neatly. Changes in mass of the scaffold before and after setting surface microscopically analyzed using SEM as shown in Figure 4.

From the scanning results, it appears that HA scaffold surface is covered evenly by IBS paste and the pores is smaller. The pore size before tested shows the distribution of values in the range of 780.8-835.4 μm and after scaffold injected by IBS in the range of 225.2 μm. It might be concluded that the IBS paste is able to evenly into the pores of the scaffold and bind hydroxyapatite in the vicinity so that crystallinity increases. Thus, IBS paste is able as bone substitution to fill the infected bone segments and vulnerable to further trigger the growth of new bone cells.

Cytotoxicity test with MTT assay

Each various samples of IBS tested in four repetitions and cell viability was calculated according to the equation (2) and then averaged as shown in Figure 5. From the test results, all sample variation of IBS is not toxic seen from the percentage of cell viability which exceeds 50% [17]. There are several samples that have a percentage of cell viability of more than 100%. This shows that fibroblasts cells capable of undergoing proliferation in the sample so that it becomes greater than the control cells. Thus, it can be concluded that the IBS paste can become new cell growth media are also expected to be a medium for the growth of osteoblast cells in bone when applied.

Microbacterium test

Based on the test results, it is known that the IBS paste is antibacterial seen from the area of inhibition zone around IBS discs with a diameter of...
of 28-33 mm (Figure 6). This inhibition zone diameter increased when incubated up to 3 days as shown in Figure 7.

The level of material strength against bacterial resistance can be evaluated by comparing the clear zone diameter by calculating the difference in bacterial inhibition zone diameter with a sample wells diameter. Obtained clear zone diameter test results in Table 2. In addition to a bone filling material, IBS paste also expected to act as drug delivery systems to evacuate the TB bacterium that encourages faster healing and achieve early spinal stability.

Conclusions

1. In the physical characteristics, IBS paste has a pH value close to normal body pH (7.3 to 7.6) and is able to maintain stability when measured in 7 days. IBS paste is injectable with the highest percentage of injectability value at 97.74% ± 0.19% and setting within 30 minutes to 1 hour when injected at HA scaffold that resembles the bone cavity and is able to cover the pore scaffold seen from the SEM results.

2. In the biological characteristics, IBS paste is not-toxic and it is antibacterial seen from inhibition zone diameter of S. aureus bacteria.

References